Dyne Therapeutics advances four DMD exon-skipping candidates into IND-enabling studies
DYN•Preclinical DMD candidates advance toward IND-enabling studies
Dyne Therapeutics flagged new preclinical data for four Duchenne muscular dystrophy candidates, with results set for presentation on Sept. 25.
The readouts are positioned to support advancement into IND-enabling studies, expanding the company’s exon-skipping franchise beyond exon 51.
The data package points to meaningful exon skipping and dystrophin production in relevant models, supporting continued development across multiple mutation subsets.
The programs use the same FORCE platform as zeleciment rostudirsen (DYNE-251), which remains under FDA review for exon 51 DMD.
